**Clinical Microbiology** 



Ann Lab Med 2019;39:587-589 https://doi.org/10.3343/alm.2019.39.6.587 ISSN 2234-3806 elSSN 2234-3814

### ANNALS OF LABORATORY MEDICINE

# First Case of *Aureimonas altamirensis* Bacteremia in Korea

Namsu Kim <sup>(b)</sup>, M.D.<sup>1</sup>, Jeong-Hwan Hwang, M.D.<sup>2,3</sup>, Yong Gon Cho <sup>(b)</sup>, M.D.<sup>1,3</sup>, Dal Sik Kim <sup>(b)</sup>, M.D.<sup>1,3</sup>, Hye Soo Lee <sup>(b)</sup>, M.D.<sup>1,3</sup>, and Jaehyeon Lee <sup>(b)</sup>, M.D.<sup>1,3</sup>

Departments of <sup>1</sup>Laboratory Medicine and <sup>2</sup>Internal Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Korea; and <sup>3</sup>Research Institute of Clinical Medicine, Chonbuk National University-Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Korea

Dear Editor,

Aureimonas altamirensis, a gram-negative, nonmotile bacterium that grows in strictly aerobic environments, was isolated from the subterranean environment of Altamira Cave in Spain in 2006 and was designated Aurantimonas altamirensis [1]; however, it was reclassified as Aureimonas altamirensis with other Aurantimonas species. In 2008, it was first isolated from clinical samples [2]. A. altamirensis has usually been implicated as a contaminant originating from the environment, such as water sources [2], and is reported as an agent of canine infection [3]. To date, only a few cases of human infections have been reported (Table 1) [4-8]. We report the first case of bacteremia by A. altamirensis in Korea. The Institutional Review Board of Chonbuk National University Hospital, Jeonju, Korea, determined that this study has a low ethical load and did not require informed consent from the patient (IRB No. CUH 2018-03-028).

A 65-year-old male presented to the emergency room of Chonbuk National University Hospital because of fever and general weakness in January 2015. Five and 10 years previously, he had been diagnosed as having diabetes mellitus and a stroke, respectively, but had been well prior to admission. On initial physical examination, the patient exhibited no unusual features, and his vital signs were normal except for a body temperature of 38.9°C. His white blood cell count was  $19 \times 10^{9}$ /L (neutrophils 96%), Hb level was 12.3 g/L, and platelet count was  $380 \times 10^{9}$ /L. Total bilirubin and direct bilirubin levels were elevated at 49.26 and 43.27 µmol/L, respectively. His AST level was 0.99 µkat/L, ALT level was 1.00 µkat/L, glycated Hb (HbA1c) level was 6.5%, and C-reactive protein level was 1,971.47 nmol/L in initial blood tests. Abdominal computed tomography showed unremarkable findings. Two sets of blood culture (FA Plus, FN Plus, BacT/Alert 3D system, bioMérieux, Durham, NC, USA) were done aseptically, and one of them was positive. From the subculture on blood agar plate incubated on 35°C with non-CO<sub>2</sub> condition for 24 hours, gravish colonies were observed. They were gram-negative bacilli that were catalase- and oxidase-positive. The isolate did not grow well in a 5% CO<sub>2</sub> condition; it grew well on both blood agar and MacConkey agar plates under non-CO<sub>2</sub> conditions but did not produce any colonies on MacConkey agar plates when incubated with 5% or 10% CO<sub>2</sub> for 24 hours. The Vitek 2 system (bioMérieux Inc., Hazelwood, MO, USA) identified this organism as Acinetobacter Iwoffii (96% probability), while the Vitek MS system (bioMérieux, Marcy L'Étoile, France) could not identify the organism. 16S ribosomal RNA sequencing (Gen-Bank, MK749933) showed 99.6% (1,361/1,366) homology with Aureimonas altamirensis (GenBank, NR\_043764.1), and the %

Received: February 19, 2019 Revision received: April 5, 2019 Accepted: May 27, 2019

**Corresponding author:** Jaehyeon Lee, M.D., Ph.D. Department of Laboratory Medicine, Chonbuk National University Medical School and Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju 54907, Korea Tel: +82-63-250-2693, Fax: +82-63-250-1200 E-mail: laboratorymedicine@gmail.com




#### © Korean Society for Laboratory Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

e Aureimonas altamirensis infections in humans
e Aureimonas altamirensis infections in humans

Case No. (N)	Year reported	Age/Sex	Clinical diagnosis	Cultured sample	Comorbidity	Treatment	Outcome	Reference
1	2009	50/M	Soft tissue infection in scrotum	Blood	Diabetes mellitus, congestive heart failure, peripheral neuropathy, hyperthyroidism, hyperlipidemia, and chronic renal failure	Vancomycin, clindamycin, ciprofloxacin	Cured	4
2	2010	69/M	Parapneumonic effusion	Blood Pleural fluid	Chronic ischemic heart disease, total gastrectomy due to gastric cancer	Levofloxacin	Cured	5
3	2010	81/M	Parapneumonic effusion	Pleural fluid	NM	Levofloxacin	Cured	5
4	2012	65/F	Bacteremia	Blood	Multiple myeloma	Levofloxacin	Cured	6
5	2014	47/F	Peritonitis	Peritoneal fluid	Peritoneal carcinomatosis with liver and lymph node metastasis	Levofloxacin	Died	7
6	2015	NM	Cellulitis on forearm, wrist, and hand	Blood	NM	Vancomycin+imipenem, TMP-SMX+clindamycin	Cured	8

Abbreviations: M, male; F, female; NM, not mentioned; TMP-SMX, trimethoprim-sulfamethoxazole.



0.010

**Fig. 1.** Phylogenetic tree analysis based on 16S ribosomal RNA gene sequences. The tree was constructed using the neighbor-joining method with bootstrap resampling (1,000 replicates). The tree was rooted with *Fluvimarina pelagi* HTCC 2615 as the outgroup. Bootstrap values are expressed as percentages of 1,000 replications, and bars represent 0.010 substitutions per nucleotide position. GenBank database accession numbers are provided near the species names.

difference with the second most highly matched organism, *Aureimonas frigidaquae* (GenBank, NR\_044195.1), was 98.4% (1,357/1,379). A phylogenetic tree analysis with representative

Aurantimonas strains downloaded from BLAST (http://www. ncbi.nlm.nih.gov/blast) was performed using MEGA X (https:// www.megasoftware.net) based on the 16S ribosomal RNA se-



quences [5, 9]. The results showed that our isolate formed a clade with the other *A. altamirensis* strains (Fig. 1).

Intravenous moxifloxacin was empirically administered, and the patient's condition improved. We performed positron emission tomography-computed tomography with [<sup>18</sup>F]-fluorodeoxy-glucose to investigate the possible causes of fever. However, the results were normal, and repeated physical examinations and imaging studies showed that the patient did not have any other infection. In addition, the follow-up blood cultures were all negative, and the patient showed a good clinical response to empirical antibiotics. Therefore, we believed that the patient had primary *A. altamirensis* bacteremia according to the clinical information obtained from 16S ribosomal RNA sequencing. The fever subsided approximately two weeks after antibiotic treatment, and the patient was discharged.

We performed an antimicrobial susceptibility testing using the E-test (bioMérieux, Marcy L'Étoile, France) after receiving the 16S ribosomal RNA sequencing result. The minimum inhibitory concentrations for amoxicillin/clavulanic acid, gentamicin, imipenem, and trimethoprim/sulfamethoxazole were 1/0.5, 2, 0.125, and >32/608 µg/mL, respectively. *A. altamirensis* was susceptible to amoxicillin/clavulanic acid and imipenem, according to the non-species related breakpoints specified by the European Committee on Antimicrobial Susceptibility Testing guidelines [10].

A PubMed Medline search identified six cases of invasive human infection by *A. altamirensis* from blood, pleural fluid, and peritoneal fluid. All patients clinically improved with antibiotics, and only one patient died because of underlying comorbidities [7].

To date, the clinical relevance of *A. altamirensis* remains uncertain [5]. However, based on previous reports and our study, it is difficult to negate its potential pathogenic significance in humans. Information on the susceptibility of *A. altamirensis* to most antibiotics is limited, and clinicians rely on only a few case reports and empirical treatments. However, most clinical isolates were susceptible to the major antibiotics used for gram-negative bacteria, except quinolone, and showed successful treatment responses [2, 4, 5, 7].

In conclusion, although there is limited information on human infections, *A. altamirensis* should be considered an opportunistic pathogen, especially in immunocompromised patients. Additionally, laboratory physicians should be careful when there are discrepancies between identification results from automated systems and biochemical tests with growth conditions.

## Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

#### Acknowledgment

This paper was supported by the Fund of Biomedical Research Institute, Chonbuk National University Hospital.

### ORCID

Namsu Kim	https://orcid.org/0000-0003-3147-5634
Yong Gon Cho	https://orcid.org/0000-0003-3011-6875
Dal Sik Kim	https://orcid.org/0000-0001-7467-2086
Hye Soo Lee	https://orcid.org/0000-0001-9391-2532
Jaehyeon Lee	https://orcid.org/0000-0003-3211-8903

### REFERENCES

- Jurado V, Gonzalez JM, Laiz L, Saiz-Jimenez C. Aurantimonas altamirensis sp. nov., a member of the order Rhizobiales isolated from Altamira Cave. Int Syst Evol Microbiol 2006;56:2583-5.
- Luong ML, Békal S, Vinh DC, Lauzon D, Leung V, Al-Rawahi GN, et al. First report of isolation and characterization of *Aurantimonas altamirensis* from clinical samples. J Clin Microbiol 2008;46:2435-7.
- Reilly TJ, Calcutt MJ, Wennerdahl LA, Williams F 3rd, Evans TJ, Ganjam IK, et al. Isolation of *Aureimonas altamirensis*, a *Brucella canis*-like bacterium, from an edematous canine testicle. J Vet Diagn Invest 2014; 26:795-8.
- 4. Mendes RE, Denys GA, Fritsche TR, Jones RN. Case report of *Auranti*monas altamirensis bloodstream infection. J Clin Microbiol 2009;47:514-5.
- Téllez-Castillo CJ, González Granda D, Bosch Alepuz M, Jurado Lobo V, Saiz-Jimenez C, Juan JL, et al. Isolation of *Aurantimonas altamirensis* from pleural effusions. J Med Microbiol 2010;59:1126-9.
- García-Lozano T, Aznar Oroval E, Juan Bañón JL. First isolation in Spain of *Aurantimonas altamirensis* in a blood culture from a port-a-cath in a patient with Bence-Jones type multiple myeloma. Enferm Infecc Microbiol Clin 2012;30:217-8.
- Schröttner P, Rudolph WW, Taube F, Gunzer F. First report on the isolation of *Aureimonas altamirensis* from a patient with peritonitis. Int J Infect Dis 2014;29:71-3.
- Eshaghi A, Shahinas D, Patel SN, Kus JV. First draft genome sequence of *Aureimonas altamirensis*, isolated from patient blood culture. FEMS Microbiol Lett 2015;362.
- Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 2018;35:1547-9.
- 10. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. http://www.eucast.org. (Updated on Jan 2019)